Alnylam Pharmace. buy The Goldman Sachs Group, Inc.
Start price
16.08.24
/
50%
€240.00
Target price
16.08.25
€336.33
Performance (%)
58.83%
End price
17.08.25
€381.20
Summary
This prediction ended on 17.08.25 with a price of €381.20. With a performance of 58.83% the BUY prediction by The_Goldman_Sachs_Gr was a big success. The_Goldman_Sachs_Gr has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -5.701% | -5.701% | 60.025% |
| iShares Core DAX® | -1.574% | -3.986% | 24.486% |
| iShares Nasdaq 100 | 0.497% | 0.999% | 17.665% |
| iShares Nikkei 225® | 2.629% | 2.466% | 10.582% |
| iShares S&P 500 | 0.150% | 1.153% | 11.199% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $370.00 price target on the stock, up previously from $198.00.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten